10th Annual Biomarkers & Diagnostics World Congress

The signature event in Cambridge Healthtech Institute's Biomarker Series, the Tenth Annual Biomarkers & Diagnostics World Congress 2014 is dedicated to all areas of biomarker research spanning the pharmaceutical and diagnostic pipeline. The meeting brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers-making the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies. The Congress also offers a balance of scientific sessions covering the latest research and strategic presentations and brainstorming sessions for the decision makers. Now in its tenth year, the Biomarkers & Diagnostics World Congress is the leading annual meeting dedicated to biomarker and diagnostics research and implementation that consistently delivers a cutting-edge agenda, 400+ senior delegates, and a sold-out exhibit hall.

The World Congress will continue offering a comprehensive coverage of biomarkers in drug development, including translational biomarkers, patient selection and drug-diagnostic co-development. The Executive Summit on Companion Diagnostics is designed to bring together drug development and diagnostics leaders to brainstorm strategies for Rx-Dx co-development, including reimbursement, regulatory, and technology/implementation strategies. The Clinical Biomarker Assay Development track, will provide complete coverage on biomarker assay development technologies, regulation, and clinical utility. Finally, a new track on Mutation Analysis for Clinical Biomarkers and Diagnostics will cover the recent research and technologies related to genomic analysis to guide clinical decision making. Please join us for comprehensive scientific coverage and unparallel networking opportunities at the Tenth Anniversary Congress!

April 29
Exosomes and Microvesicles as Cancer Biomarkers

April 30
Fit-for-Purpose Biomarker Assay Development and Validation

Non-Coding RNAs as Biomarkers and Diagnostics

May 1
Next-Generation Sequencing as a Clinical Test
Laboratory-Developed Tests

+ show speakers and program
Distinguished Faculty

John L. Allinson, FIBMS, Head, Biomarker Strategy, Drug Development Services, LGC

Jiri Aubrecht, Pharm.D., Ph.D., Senior Director and Safety Biomarker Group Lead, Drug Safety Research & Development, Pfizer

Michael Berger, Ph.D., Assistant Professor, Pathology, Memorial Sloan-Kettering Cancer Center

Mark S. Boguski, M.D., Ph.D., Associate Professor, Pathology, Center for Biomedical Informatics, Harvard Medical School

Darrell R. Borger, Ph.D., Co-Director, Translational Research Laboratory; Director, Biomarker Laboratory, Massachusetts General Hospital and Harvard Medical School

Michael Burczynski, Ph.D., Executive Director, Biomarker Technologies, Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb

Tracy Bush, Ph.D., Director, Companion Diagnostics Regulatory Affairs, Roche Diagnostics

Derek Chiang, Ph.D., Research Investigator, Novartis Institutes for Biomedical Research

Charles J. Cox, Ph.D., Head, Genetics Experiment Design and Delivery, GlaxoSmithKline

Seth Crosby, M.D., Director, Partnerships & Alliances, Washington University School of Medicine

Mark E. Curran, Ph.D., Vice President, Immunology, Systems Pharmacology & Biomarkers, Janssen Research & Development

Viswanath Devanarayan, Ph.D., Global Head, Exploratory Statistics, AbbVie, Inc.

Marisa Dolled-Filhart, Ph.D., Associate Director, Pathology and Companion Diagnostics, Merck

Michael J. Donovan, M.D., Ph.D., Director, Experimental Pathology, Mt. Sinai School of Medicine

Nicholas C. Dracopoli, Ph.D., Vice President, Janssen R&D, Johnson & Johnson

Daniel Edelman, Ph.D., Core Manager, Clinical Molecular Profiling Core, National Cancer Institute, NIH

Andrea Ferreira-Gonzalez, Ph.D., Professor and Chair, Division of Molecular Diagnostics; Director, Molecular Diagnostics Laboratory, Department of Pathology, Virginia Commonwealth University

Helen Fernandes, Ph.D., Associate Professor, Pathology and Laboratory Medicine, Weill Cornell Medical College

Andrew Fish, Executive Director, AdvaMedDx

Felix W. Frueh, Ph.D., Executive Partner, Opus Three, LLC

Iris Grossman, Ph.D., Global Head, Personalized Medicine and Pharmacogenomics, Teva Pharmaceutical

Steven Gutman, M.D., Strategic Advisor, Myraqa

Michael Hale, Ph.D., Executive Director, Medical Sciences Biostatistics, Amgen

Sam Hanash, M.D., Ph.D., Director, McCombs Institute for Cancer Early Detection and Treatment, MD Anderson Cancer Center

Xiaolan Hu, Ph.D., Head, Clinical Genetics, Bristol Myers Squibb

Bing-Hua Jiang, Ph.D., Professor, Pathology, Anatomy and Cell Biology, Thomas Jefferson University

Peter M. Kazon, General Counsel, American Clinical Laboratory Association

Iya Khalil, Ph.D., Executive Vice President and Co-Founder, GNS Healthcare

Marc Ladanyi, M.D., William Ruane Chair in Molecular Oncology; Molecular Diagnostics Service and Human Oncology & Pathogenesis Program, Memorial Sloan-Kettering Cancer Center

Eric Lai, Ph.D., Senior Vice President and Head, Pharmacogenomics, Takeda Pharmaceuticals International

Eunice Lee, Ph.D., Regulatory Scientist, Office of In Vitro Diagnostics and Radiological Health, CDRH, FDA

Laurent Lessard, Ph.D., Assistant Professor, Molecular Oncology, John Wayne Cancer Institute

Towia Libermann, Ph.D., Associate Professor, Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School; Director, BIDMC Genomics, Proteomics, Bioinformatics, and Systems Biology Center and DF/HCC Cancer Proteomics Core

Walter Lukiw, Ph.D., Professor, Neuroscience, Louisiana State University

Rajyalakshmi Luthra, Ph.D., Professor, Hematopathology; Director, Molecular Genetic Pathology Fellowship Program; Director, Molecular Diagnostic Laboratory, MD Anderson Cancer Center

Ron Mazumder, Ph.D., MBA, Global Head, R&D and Operations, Janssen Diagnostics, Janssen Pharmaceutical Companies of Johnson & Johnson

Donna L. Mendrick, Ph.D., Director, Systems Biology, NCTR, FDA

Christopher-Paul Milne, DVM, MPH, J.D., Assistant Research Professor, Director, Research, Center for the Study of Drug Development, Tufts University Medical School

Nirmala Nanguneri, Ph.D., Director and Head, Biomarker Analysis and Informatics, Novartis Institutes for Biomedical Research

Jonathan Pan, Director, Oncology Companion Diagnostic & Disease Strategy, GlaxoSmithKline

Saumya Pant, Ph.D., Research Fellow, Merck

Abhijit Patel, M.D., Ph.D., Assistant Professor, Therapeutic Radiology, Yale University School of Medicine

Rajesh Patel, Ph.D., Scientific Manager, Oncology Biomarker Development, Genentech

Scott D. Patterson, Ph.D., Executive Director, Medical Sciences, Amgen

Suso Platero, Ph.D., Director, Oncology Biomarkers, Janssen Pharmaceuticals

Victor Prieto, M.D., Ph.D., Professor, Pathology and Dermatology, MD Anderson Cancer Center

Mitch Raponi, Ph.D., Senior Director, Molecular Diagnostics, Clovis Oncology

Tarek Sahmoud, M.D., Ph.D., Corporate Vice President, Clinical Research and Development, Celgene Corporation

Andrew Schade, M.D., Ph.D., Senior Director, Diagnostics and Experimental Pathology, Tailored Therapeutics, Eli Lilly and Company

Cecilia Schott, Pharm.D., MBA, Head, Personalized Healthcare, Corporate Business Development, AstraZeneca

Andreas Schuppert, Ph.D., Vice President, Technology Development, Bayer Technology Services GmbH; Professor, AICES, RWTH Aachen University

Corinne Solier, Ph.D., Leader, ClinicalProtein Biomarkers, F. Hoffmann-La Roche

Kári Stefánsson, M.D., CEO, deCODE Genetics

Douglas D. Taylor, Ph.D., CSO, Exosome Sciences

Liling Warren, Ph.D., Senior Scientific Investigator, GlaxoSmithKline

Bo Wei, MS, Associate Principal Scientist, Molecular Biomarker and Diagnostics, Merck

Jens R. Wendland, M.D., Director and Head, Neuroscience Genetics, Pfizer Worldwide R&D

P. Mickey Williams, Ph.D., Director, Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research

Huiqing Wu, M.D., Assistant Professor, Pathology, City of Hope National Medical Center and Beckman Research Institute

Hang Hubert Yin, Ph.D., Associate Professor, Chemistry and Biochemistry, University of Colorado Boulder

Jenny Zhang, Ph.D., Senior Scientist, Pfizer

30 Apr - 2 May 2014
United States of America
meeting website